Jiangsu Hengrui Pharmaceuticals Co.,Ltd (SHA:600276)
China flag China · Delayed Price · Currency is CNY
46.07
-1.25 (-2.64%)
Aug 31, 2026, 3:00 PM CST

SHA:600276 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
27,70828,01325,01022,37721,21325,780
Other Revenue
3,6163,6162,975442.662.25125.22
31,32431,62927,98522,82021,27525,906
Revenue Growth
3.91%13.02%22.63%7.26%-17.87%-6.59%
Cost of Revenue
4,4484,4503,8813,5623,5033,756
Gross Profit
26,87627,18024,10419,25717,77222,150
Selling, General & Admin
11,83711,91310,8929,9949,65412,244
Research & Development
7,2266,9616,5834,9544,8875,943
Other Operating Expenses
282.64200.79182.17149.03145.32201.81
Operating Expenses
19,36419,09417,62815,08114,71218,385
Operating Income
7,5118,0866,4764,1763,0603,765
Interest Expense
-14.35-14.35-5.56-5.9-6.49-4.71
Interest & Investment Income
785.39785.39607.56477.14772.64580.9
Currency Exchange Gain (Loss)
-363.38-363.38-24.047.993.19-22.42
Other Non Operating Income (Expenses)
-249.68-5.57-0.610.74-1.37-198.97
EBT Excluding Unusual Items
7,6698,4887,0534,6563,9184,119
Gain (Loss) on Sale of Investments
784.3693.39108.63-107.4176.536.23
Gain (Loss) on Sale of Assets
42.374.055.43.164.231.64
Asset Writedown
-12.18-3.29-4.94-76.21-130-
Other Unusual Items
125.15125.157.55191.68100.11309.04
Pretax Income
8,6098,7087,1704,6673,9684,466
Income Tax Expense
881.49990.62832.7389.29153.35-17.72
Earnings From Continuing Operations
7,7287,7176,3374,2783,8154,484
Minority Interest in Earnings
-1.23-5.95-0.4724.6291.2346.19
Net Income
7,7267,7116,3374,3023,9064,530
Net Income to Common
7,7267,7116,3374,3023,9064,530
Net Income Growth
5.05%21.69%47.28%10.14%-13.77%-28.41%
Shares Outstanding (Basic)
6,5856,4806,3376,3276,4046,381
Shares Outstanding (Diluted)
6,6406,5356,3376,3276,4046,381
Shares Change
4.76%3.13%0.15%-1.20%0.36%-0.18%
EPS (Basic)
1.171.191.000.680.610.71
EPS (Diluted)
1.161.181.000.680.610.71
EPS Growth
0.27%18.00%47.06%11.47%-14.09%-28.28%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
5,6508,2735,4546,160-726.912,554
Free Cash Flow Per Share
0.851.270.860.97-0.110.40
Dividend Per Share
0.2000.2000.2000.2000.1600.160
Dividend Growth
0%0%0%25.00%0%-4.02%
Gross Margin
85.80%85.93%86.13%84.39%83.53%85.50%
Operating Margin
23.98%25.57%23.14%18.30%14.38%14.53%
Profit Margin
24.67%24.38%22.64%18.85%18.36%17.49%
Free Cash Flow Margin
18.04%26.16%19.49%26.99%-3.42%9.86%
EBITDA
8,4028,8897,1984,8433,5994,260
EBITDA Margin
26.82%28.10%25.72%21.22%16.91%16.45%
D&A For EBITDA
890.43802.4722.29666.52539.12495.59
EBIT
7,5118,0866,4764,1763,0603,765
EBIT Margin
23.98%25.57%23.14%18.30%14.38%14.53%
Effective Tax Rate
10.24%11.38%11.61%8.34%3.86%-
Revenue as Reported
31,62931,62927,98522,82021,27525,906